| tofacitinib / Generic mfg. |
| Completed | N/A | 162 | Japan, US, Canada, Europe, RoW | CP-690,550 | Pfizer | Arthritis, Rheumatoid | 02/12 | 02/12 | | |
| Completed | N/A | 83 | US, Canada, Europe, RoW | Tofacitinib | Pfizer | Kidney Transplantation | 07/12 | 07/12 | | |
NCT05576051: To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting. |
|
|
| Completed | N/A | 1 | US | patterns of use of combination therapy and monotherapy | Pfizer | Rheumatoid Arthritis | 10/15 | 10/15 | | |
NCT03975790: Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX |
|
|
| Completed | N/A | 479 | US | | Pfizer | Rheumatoid Arthritis | 10/18 | 10/18 | | |
NCT04018001: Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR) |
|
|
| Completed | N/A | 1057 | US | | Pfizer | Rheumatoid Arthritis | 04/19 | 04/19 | | |
NCT04267380: A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day |
|
|
| Completed | N/A | 298 | US | | Pfizer | Arthritis Rheumatoid | 08/19 | 08/19 | | |
NCT03073109: Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions |
|
|
| Completed | N/A | 170 | RoW | | Pfizer | Arthritis, Rheumatoid | 09/19 | 09/19 | | |
NCT04047121: A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients |
|
|
| Completed | N/A | 1349 | US | | Pfizer | Rheumatoid Arthritis | 10/19 | 10/19 | | |
NCT03703817: Rheumatoid Arthritis Satisfaction Outcome Research |
|
|
| Completed | N/A | 421 | RoW | | Pfizer, Biostatistics, Preventive Medicinte Department, College of Medicine, Yonsei University | Rheumatoid Arthritis | 03/20 | 03/20 | | |
NCT03964649: Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics |
|
|
| Completed | N/A | 7308 | US | | Pfizer | Arthritis, Rheumatoid | 04/20 | 04/20 | | |
| Terminated | N/A | 50 | Europe | | Ced Service GmbH, Pfizer | Colitis, Ulcerative, Biologics, Tofacitiniib, Chronic Inflammatory Small Bowel Disease, Bowel Diseases, Inflammatory, Bowel Disease, CED | 11/20 | 11/20 | | |
NCT01932372: Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis |
|
|
| Completed | N/A | 9968 | Japan | Tofacitinib (Xeljanz), Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc | Pfizer | Rheumatoid Arthritis | 08/21 | 08/21 | | |
|
NCT04721808: A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis |
|
|
| Completed | N/A | 1712 | US | | Pfizer | Arthritis, Rheumatoid | 11/21 | 11/21 | | |
NCT04721821: Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy. |
|
|
| Completed | N/A | 7807 | US | Tofacitinib | Pfizer | Arthritis Rheumatoid | 11/21 | 11/21 | | |
| Completed | N/A | 1040 | RoW | | Pfizer | Rheumatoid Arthritis, Psoriatic Arthritis | 06/22 | 06/22 | | |
NCT04071405: Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients |
|
|
| Completed | N/A | 110 | RoW | Non-intervention | Pfizer | Ulcerative Colitis | 09/22 | 09/22 | | |
NCT05572567: Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis |
|
|
| Completed | N/A | 1 | Japan | | Pfizer | Arthritis, Rheumatoid | 10/22 | 10/22 | | |
NCT05082428: This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data. |
|
|
| Completed | N/A | 1 | Europe | | Pfizer | Ulcerative Colitis | 11/22 | 11/22 | | |
NCT03643211: Xeljanz Special Investigation for Long-term Use in UC Patients |
|
|
| Completed | N/A | 2043 | Japan | | Pfizer | Ulcerative Colitis | 11/22 | 11/22 | | |
NCT05487703: A Study To Describe The Use Of Tofacitinib After Use Of Rituximab In Patients With Rheumatoid Arthritis In A Real-World Setting |
|
|
| Completed | N/A | 1 | RoW | | Pfizer | Arthritis, Rheumatoid | 12/22 | 12/22 | | |
NCT03981900: IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis |
|
|
| Completed | N/A | 314 | Europe | Tofacitinib, Xeljanz | Pfizer | Arthritis, Rheumatoid | 02/23 | 02/23 | | |
| Completed | N/A | 198 | Europe | | Pfizer | Rheumatoid Arthritis | 02/23 | 02/23 | | |
TOFAT, NCT04175886: Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the Project |
|
|
| Terminated | N/A | 10 | Europe | Tofacitinib | University Hospital, Lille, Pfizer | Rheumatoid Arthritis | 05/23 | 05/23 | | |
TOPRA, NCT03815578: Evaluation of Pain Sensitization in Rheumatoid Arthritis: Analysis on a Cohort of Tofacitinib Treated Patients |
|
|
| Completed | N/A | 20 | Europe | Clinical examination, Pain assessment, blood sample, Patient Reported Outcomes | University Hospital, Bordeaux, Pfizer | Rheumatoid Arthritis | 04/23 | 04/23 | | |
ESCALATE-RA, NCT03387423: Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis |
|
|
| Completed | N/A | 1497 | Europe | Tofacitinib | Pfizer | Arthritis, Rheumatoid | 07/23 | 07/23 | | |
KIC-START, NCT05069259: Generate Real World Data On Tofacitinib Induction Therapy and Changes In Clinical and Patient Reported Outcomes. |
|
|
| Recruiting | N/A | 60 | Europe | Stool sample collection | Pfizer | Ulcerative Colitis | 10/24 | 10/24 | | |
TOUR, NCT03772145: Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study |
|
|
| Terminated | N/A | 103 | US | | University of North Carolina, Chapel Hill, Pfizer | Ulcerative Colitis | 01/23 | 01/24 | | |
PASS TOFA, NCT06469424: An Active Surveillance, Post-Authorization Study to Characterize the Safety of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data From the United Registries for Clinical Assessment and Research (UR-CARE) in the European Union (EU) |
|
|
| Recruiting | N/A | 104 | Europe | | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa, Pfizer | Ulcerative Colitis | 03/25 | 03/26 | | |
NCT03992781: Changes of Depression After First-year of Tofacitinib in RA Patients |
|
|
| Completed | N/A | 73 | RoW | | Pfizer | Rheumatoid Arthritis | 02/24 | 02/24 | | |
NCT05195814: A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis |
|
|
| Completed | N/A | 1 | US | | Pfizer | Psoriatic Arthritis | 10/23 | 10/23 | | |
NCT06418529: A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis |
|
|
| Active, not recruiting | N/A | 20000 | US | tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab | Pfizer | Rheumatoid Arthritis | 07/24 | 07/24 | | |
TOPSATI, NCT04517669: Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice |
|
|
| Recruiting | N/A | 500 | Europe, RoW | | Pfizer | Psoriatic Arthritis | 07/24 | 07/24 | | |
| Recruiting | N/A | 280 | Europe | Tofacitinib | Pfizer | Ulcerative Colitis | 06/26 | 06/26 | | |
ODEN, NCT04338204: Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden |
|
|
| Recruiting | N/A | 120 | Europe | tofacitinib | Pfizer | Ulcerative Colitis | 08/26 | 08/26 | | |
| Active, not recruiting | N/A | 375 | RoW | Xeljanz | Pfizer | Psoriatic Arthritis, Juvenile, Polyarticular Juvenile Idiopathic Arthritis | 01/27 | 01/27 | | |
